International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN. 

Short Review Paper on Drug Lag and Rare Disease Treatments in India: An Urgent Call for Actions

    ,

Author Affiliations

  • 1M.L. Schroff School of Pharmacy, Dr. C.V. Raman University, Khandwa, MP, India
  • 2M.L. Schroff School of Pharmacy, Dr. C.V. Raman University, Khandwa, MP, India

Res. J. of Pharmaceutical Sci., Volume 14, Issue (1), Pages 15-16, June,30 (2025)

Abstract

Drug lag, the delay in the availability of new medications, poses a significant challenge for patients with rare diseases in India. This paper examines the impact of drug lag on rare disease treatments in India, explores the regulatory and systemic factors contributing to these delays, and proposes strategies to mitigate the issue. By conducting a thorough examination of scholarly sources and policy analysis, the paper underscores the urgent need for regulatory reform and enhanced patient access to rare disease treatments.

References

  1. Fondation Ipsen. (2020)., 7,000 challenges: the basis and burden of rare diseases., Environmental Management and Health, 7(3), 28-36.
  2. Taneja, A., Shashidhara, L. S., & Bhattacharya, A. (2020)., Rare diseases in India: Challenges and opportunities., Indian Journal of Pediatrics, 87(8), 611-616.
  3. Prorelix Research. (2023)., Changes to CDSCO’s Rules for Clinical Trials in India: New Drugs & Clinical Trial Rules 2019., Prorelix Research Journal, 7(1), 18-22.
  4. Chaudhary, K., & Malhotra, P. (2023)., Drug lag in India: Analyzing regulatory differences and challenges in rare disease treatment., Journal of Clinical Pharmacy and Therapeutics, 48(2), 305-310.
  5. Sharma, P., & Deshmukh, R. (2024)., Policy strategies to mitigate drug lag and foster rare disease treatment innovation in India. Journal of Health Policy and Innovation, 12(1), 33-40., undefined
  6. Reddy, K., & Mehta, V. (2024). Incentives for rare disease drug development in India: Tax benefits, orphan drug designation, and public-private partnerships., Journal of Drug Development and Innovation, 14(2), 85-92., undefined
  7. Verma, S., & Gupta, A. (2024)., Regulatory barriers in rare disease treatment approvals: A comparative study., Indian Journal of Regulatory Affairs, 31(1), 22-30.
  8. Mishra, D., & Kulkarni, P. (2023)., Market exclusivity for rare disease drugs: A global perspective., Journal of Pharmaceutical Economics, 27(3), 70-78.
  9. Singh, N., & Chatterjee, M. (2023)., The evolving role of CDSCO in rare disease management., Indian Journal of Clinical Research, 19(2), 55-61.
  10. Patel, R., & Roy, S. (2024)., Expedited approval pathways for orphan drugs: A review of global best practices., ISCA Journal of Pharmacology, 15(2), 105-112.
  11. Agarwal, K., & Bose, T. (2024)., Challenges in Indian orphan drug policy and recommendations for improvement., Journal of Medical Policy and Research, 18(1), 45-58.
  12. Sharma, V., & Rao, M. (2024)., The role of artificial intelligence in streamlining drug approval processes., Journal of Biomedical Research, 20(2), 99-110.